Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Ionis Pharmaceuticals Inc patents


Recent patent applications related to Ionis Pharmaceuticals Inc. Ionis Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Ionis Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Ionis Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Ionis Pharmaceuticals Inc-related inventors


Modulation of transthyretin expression

Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. ... Ionis Pharmaceuticals Inc

Modulation of transthyretin expression

Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. ... Ionis Pharmaceuticals Inc

Modulation of transthyretin expression

Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. ... Ionis Pharmaceuticals Inc

Modulation of transthyretin expression

Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. ... Ionis Pharmaceuticals Inc

Modulation of transthyretin expression

Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. ... Ionis Pharmaceuticals Inc

Modulation of transthyretin expression

Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. ... Ionis Pharmaceuticals Inc

Modulation of transthyretin expression

Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. ... Ionis Pharmaceuticals Inc

Modulation of transthyretin expression

Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. ... Ionis Pharmaceuticals Inc

Modulation of transthyretin expression

Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. ... Ionis Pharmaceuticals Inc

Modulation of transthyretin expression

Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. ... Ionis Pharmaceuticals Inc

Modified crispr rna and modified single crispr rna and uses thereof

The present disclosure provides compounds comprising modified oligonucleotides for use in crispr. In certain embodiments, such modified oligonucleotides provide improved properties of crrna. ... Ionis Pharmaceuticals Inc

Allele specific modulators of p23h rhodopsin

The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (rp), such as autosomal dominant retinitis pigmentosa (adrp) by administering a p23h rhodopsin specific inhibitor to a subject. The present embodiments provided herein are directed to compounds and compositions useful for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (rp), such as autosomal dominant retinitis pigmentosa (adrp). ... Ionis Pharmaceuticals Inc

Compounds and methods for increasing antisense activity

In certain embodiments, the present disclosure provides compounds and methods for increasing the antisense activity of an antisense compound in a cell. In certain embodiments, the present disclosure provides methods for identifying antisense compounds having high activity. ... Ionis Pharmaceuticals Inc

Modulation of angiopoietin-like 3 expression

Provided herein are methods, compounds, and compositions for reducing expression of an angptl3 mrna and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. ... Ionis Pharmaceuticals Inc

05/10/18 / #20180127758

Modulation of nuclear-retained rna

Provided herein are methods, compounds, and compositions for reducing expression of a a nrrna in an animal. Also provided herein are methods, compounds, and compositions for treating, ameliorating, delaying or reducing a symptom of a disease or disorder associated with a nuclear-retained rna in an animal. ... Ionis Pharmaceuticals Inc

05/10/18 / #20180127751

Antisense compounds targeting genes associated with fibronectin

The present invention provides compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. ... Ionis Pharmaceuticals Inc

05/03/18 / #20180119145

Compounds and methods for reducing tau expression

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of tau mrna in a cell or animal, and in certain instances reducing the amount of tau protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. ... Ionis Pharmaceuticals Inc

05/03/18 / #20180119142

Compositions for modulating expression of c9orf72 antisense transcript

Disclosed herein are compositions and methods for modulating expression of c9orf72 antisense transcript in a cell or animal with c9orf72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. ... Ionis Pharmaceuticals Inc

04/19/18 / #20180105817

Compounds and methods for modulating tmprss6 expression

Disclosed herein are compositions and compounds comprising modified oligonucleotides for modulating tmprss6 and modulating an iron accumulation disease, disorder and/or condition in an individual in need thereof. Iron accumulation diseases in an individual such as polycythemia, hemochromatosis or β-thalassemia can be treated, ameliorated, delayed or prevented with the administration of antisense compounds targeted to tmprss6.. ... Ionis Pharmaceuticals Inc

04/19/18 / #20180104272

2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations

Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2′-och3 substituent group on a sugar moiety. ... Ionis Pharmaceuticals Inc

04/19/18 / #20180104271

2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations

Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2′-och3 substituent group on a sugar moiety. ... Ionis Pharmaceuticals Inc

04/05/18 / #20180094261

Compositions for modulating tau expression

Disclosed herein are antisense compounds and methods for decreasing tau mrna and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate tau-associated diseases, disorders, and conditions.. ... Ionis Pharmaceuticals Inc

03/29/18 / #20180087107

Competitive modulation of micrornas

The present invention provides compounds and methods for competitive modulation of micrornas. Such copounds and methods have profound effects on cells.. ... Ionis Pharmaceuticals Inc

03/29/18 / #20180087052

Modulation of huntingtin expression

Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mrna and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate huntington's disease, or a symptom thereof.. ... Ionis Pharmaceuticals Inc

03/15/18 / #20180073022

Modulation of alpha synuclein expression

Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mrna and protein expression. Also disclosed herein are methods for treating, preventing, and ameliorating neurodegenerative diseases in an individual in need thereof.. ... Ionis Pharmaceuticals Inc

02/22/18 / #20180051283

Compositions and methods for modulating tau expression

Disclosed are methods for modulating splicing of tau mrna in an animal with tau antisense compounds. Also disclosed herein are methods for reducing expression of tau mrna and protein in an animal with tau antisense compounds. ... Ionis Pharmaceuticals Inc

02/15/18 / #20180044676

Compositions and methods for modulating ttr expression

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to n-acetylgalactosamine.. ... Ionis Pharmaceuticals Inc

02/15/18 / #20180044370

Method for solution phase detritylation of oligomeric compounds

Provided herein are methods for removal of monomethoxytrityl groups from oligomeric compounds comprising terminally linked monomethoxytrityl protected amino groups. The present methods differ from standard methods for 5′-dimethoxytrityl removal from oligonucleotides in that the present methods are performed at elevated temperatures and higher ph. ... Ionis Pharmaceuticals Inc

02/08/18 / #20180036335

Compositions for modulating mecp2 expression

Disclosed herein are compounds and methods for decreasing methyl cpg binding protein 2 (mecp2) mrna and protein expression. Such compounds and methods are useful to treat, prevent, or ameliorate mecp2 associated disorders and syndromes. ... Ionis Pharmaceuticals Inc

02/01/18 / #20180028555

2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations

Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2′-och3 substituent group on a sugar moiety. ... Ionis Pharmaceuticals Inc

01/25/18 / #20180023077

Compositions for modulating expression of c9orf72 antisense transcript

Disclosed herein are compositions and methods for reducing expression of c9orf72 antisense transcript in an animal with c9orf72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. ... Ionis Pharmaceuticals Inc

01/11/18 / #20180010126

Antisense compounds and uses thereof

The present disclosure provides oligomeric compounds. The present disclosure provides metabolically stable linkers that do not rapidly degrade in vivo. ... Ionis Pharmaceuticals Inc

01/11/18 / #20180009837

Compounds and methods for the modulation of proteins

In certain embodiments, the present disclosure provides compounds and methods of increasing the amount or activity of a target protein in a cell. In certain embodiments, the compounds comprise a translation suppression element inhibitor. ... Ionis Pharmaceuticals Inc

01/04/18 / #20180002695

Compounds and methods for improved cellular uptake of antisense compounds

The present invention provides method of increasing the efficacy and potency of antisense compounds. In certain embodiments, the invention provides methods for improved cellular uptake.. ... Ionis Pharmaceuticals Inc

01/04/18 / #20180002693

Compositions and methods

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to n-acetylgalactosamine.. ... Ionis Pharmaceuticals Inc

12/28/17 / #20170369883

Modulation of hepatitis b virus (hbv) expression

Disclosed herein are antisense compounds and methods for decreasing hbv mrna, dna and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hbv-related diseases, disorders or conditions.. ... Ionis Pharmaceuticals Inc

12/28/17 / #20170369880

Compositions comprising alternating 2'-modified nucleosides for use in gene modulation

The present invention provides compositions comprising at least one oligomeric compound comprising an alternating motif and further include a region that is complementary to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. ... Ionis Pharmaceuticals Inc

12/21/17 / #20170362592

Modulation of ube3a-ats expression

Certain embodiments are directed to methods and compounds for inhibiting ube3a-ats, the endogenous antisense transcript of ubiquitin protein ligase e3a (ube3a). Such methods and compounds are useful for. ... Ionis Pharmaceuticals Inc

12/14/17 / #20170355727

Conjugated antisense compounds and their use

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to n-acetylgalactosamine or to n-acetylgalactosamine analogues.. ... Ionis Pharmaceuticals Inc

12/07/17 / #20170349897

Compositions for modulating c9orf72 expression

Disclosed herein are compositions and methods for reducing expression of c9orf72 mrna and protein in an animal. Such methods are useful to treat, prevent, ameliorate, or slow progression of neurodegenerative diseases in an individual in need thereof.. ... Ionis Pharmaceuticals Inc

11/30/17 / #20170342420

Methods for treating hypercholesterolemia

Disclosed herein are antisense compounds and methods for decreasing ldl-c in an individual having elevated ldl-c. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. ... Ionis Pharmaceuticals Inc

11/23/17 / #20170335329

Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.. . ... Ionis Pharmaceuticals Inc

11/16/17 / #20170327893

Methods of predicting toxicity

Described herein are compounds useful for the treatment and investigation of diseases, methods for the prediction of in vivo toxicity of compounds useful for the treatment and investigation of diseases, and methods of discovering and identifying compounds useful for the treatment and investigation of diseases that have reduced in vivo toxicity.. . ... Ionis Pharmaceuticals Inc

11/16/17 / #20170327824

Selective antisense compounds and uses thereof

The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. ... Ionis Pharmaceuticals Inc

11/16/17 / #20170327527

Method for solution phase detritylation of oligomeric compounds

Provided herein are methods for the synthesis of oligomeric compounds wherein removal of the 5′-terminal trityl group is performed at reduced temperature and lower ph relative to standard methods. In certain embodiments, the present methods provide detritylated oligomeric compounds having a reduced percentage of depurination relative to the same detritylated oligomeric compounds prepared using standard methods. ... Ionis Pharmaceuticals Inc

11/09/17 / #20170321216

Modulation of agpat5 expression

Provided herein are methods, compounds, and compositions for reducing expression of an agpat5 mrna and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids, insulin resistance and/or glucose in an animal. ... Ionis Pharmaceuticals Inc

10/05/17 / #20170283804

Antisense compounds and uses thereof

The present disclosure provides methods for sensitizing a cell for modulation by oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. ... Ionis Pharmaceuticals Inc

09/28/17 / #20170275620

Modulation of apolipoprotein c-iii expression

Compounds, compositions and methods are provided for modulating the expression of apolipoprotein c-iii. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein c-iii. ... Ionis Pharmaceuticals Inc

09/21/17 / #20170268004

Modulation of apolipoprotein ciii (apociii) expression

Provided herein are methods, compounds, and compositions for reducing expression of apociii mrna and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing hdl levels and/or improving the ratio of tg to hdl and reducing plasma lipids and plasma glucose in an animal. ... Ionis Pharmaceuticals Inc

08/17/17 / #20170233732

Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations

Provided herein are methods, compounds, and compositions for reducing expression of apociii mrna and protein in a patient with fredrickson type i dyslipidemia, fcs, lpld. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating fredrickson type i dyslipidemia, fcs, lpld, in a patient. ... Ionis Pharmaceuticals Inc

07/27/17 / #20170211064

Compositions and methods for modulating tau expression

Disclosed herein are methods for reducing expression of tau mrna and protein in an animal with tau antisense compounds. Also disclosed are methods for modulating splicing of tau mrna in an animal with tau antisense compounds. ... Ionis Pharmaceuticals Inc

07/27/17 / #20170211062

Antisense oligonucleotide compositions

The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. ... Ionis Pharmaceuticals Inc

06/29/17 / #20170183661

Compositions and methods for modulating pkk expression

Disclosed herein are antisense compounds and methods for decreasing pkk mrna and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate pkk-associated diseases, disorders, and conditions.. ... Ionis Pharmaceuticals Inc

06/29/17 / #20170183373

Nucleoside derivatives as inhibitors of rna-dependent rna viral polyermase

The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of rna-dependent rna viral polymerase. These compounds are inhibitors of rna-dependent rna viral replication and are useful for the treatment of rna-dependent rna viral infection. ... Ionis Pharmaceuticals Inc

06/29/17 / #20170182084

Methods and compositions for modulating apolipoprotein (a) expression

Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or lp(a). Certain diseases, disorders or conditions related to apo(a) or lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. ... Ionis Pharmaceuticals Inc

06/29/17 / #20170182082

Antisense compounds

Provided herein are gapmer oligomeric compounds for reduction of target rna in vivo comprising different nucleotide modifications within one or both wing regions. Also provided are methods of using such oligomeric compounds, including use in animals. ... Ionis Pharmaceuticals Inc

06/22/17 / #20170175114

Compositions for modulating ataxin 2 expression

Disclosed herein are antisense compounds and methods for decreasing ataxin 2 mrna and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate ataxin 2 associated diseases, disorders, and conditions. ... Ionis Pharmaceuticals Inc

06/15/17 / #20170166899

Compositions and methods for modulating growth hormone receptor expression

The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating a disease associated with excess growth hormone using antisense compounds oligonucleotides targeted to growth hormone receptor (ghr).. . ... Ionis Pharmaceuticals Inc

06/08/17 / #20170159055

Compositions and methods for modulating complement factor b expression

The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a complement factor b (cfb) specific inhibitor to a subject.. . ... Ionis Pharmaceuticals Inc

05/11/17 / #20170130224

Linkage modified gapped oligomeric compounds and uses thereof

The present invention provides gapped oligomeric compounds. More particularly the gapped oligomeric compounds provided herein comprise at least one modified internucleoside linkage in the gap region. ... Ionis Pharmaceuticals Inc

05/04/17 / #20170121710

Methods and compositions for modlating apolipoprotein (a) expression

Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or lp(a). Certain diseases, disorders or conditions related to apo(a) or lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. ... Ionis Pharmaceuticals Inc

03/16/17 / #20170073689

Modulators of growth hormone receptor

The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating a disease associated with excess growth hormone using antisense compounds oligonucleotides targeted to growth hormone receptor (ghr).. . ... Ionis Pharmaceuticals Inc

03/16/17 / #20170073688

Modulation of tmprss6 expression

Disclosed herein are antisense compounds and methods for modulating tmprss6 and modulating an iron accumulation disease, disorder and/or condition in an individual in need thereof. Iron accumulation diseases in an individual such as hemochromatosis or β-thalassemia can be ameliorated or prevented with the administration of antisense compounds targeted to tmprss6.. ... Ionis Pharmaceuticals Inc

02/16/17 / #20170044539

Oligomeric compounds comprising alpha-beta-constrained nucleic acid

The present disclosure provides oligomeric compounds comprising at least one α-β-constrained nucleic acid as provided herein. More particularly, the α-β-constrained nucleic acid provided herein comprise an optionally modified nucleoside with a phosphorus containing constrained internucleoside linkage such as for example a cyclic phosphate internucleoside linkage. ... Ionis Pharmaceuticals Inc

02/16/17 / #20170044526

Linkage modified oligomeric compounds

The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. ... Ionis Pharmaceuticals Inc

02/16/17 / #20170043025

Method for synthesis of reactive conjugate clusters

Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. ... Ionis Pharmaceuticals Inc

02/09/17 / #20170037410

Compositions for modulating sod-1 expression

Disclosed herein are antisense compounds and methods for decreasing sod-1 mrna and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate sod-1 associated diseases, disorders, and conditions. ... Ionis Pharmaceuticals Inc

02/09/17 / #20170037409

Modulation of angiopoietin-like 3 expression

Provided herein are methods, compounds, and compositions for reducing expression of an angptl3 mrna and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. ... Ionis Pharmaceuticals Inc

02/09/17 / #20170035798

Modulation of factor 11 expression

Disclosed herein are antisense compounds and methods for decreasing factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. ... Ionis Pharmaceuticals Inc

01/05/17 / #20170002359

Modulation of prekallikrein (pkk) expression

Disclosed herein are antisense compounds and methods for decreasing pkk mrna and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate pkk-associated diseases, disorders, and conditions.. ... Ionis Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Ionis Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Ionis Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###